In the past 2 years, the FDA has approved 3 new drugs for prevention or treatment of hereditary angioedema (HAE) in non-pregnant adolescents and adults: the C1 esterase inhibitor Cinryze for prophylaxis and the C1 esterase inhibitor Berinert and the kallikrein inhibitor ecallantide (Kalbitor) for treatment of acute attacks.

Market Analysis and Insights: Global Hereditary Angioedema Drug Market
The global Hereditary Angioedema Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Hereditary Angioedema Drug Scope and Market Size
Hereditary Angioedema Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Hereditary Angioedema Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Hereditary Angioedema Drug market is segmented into
C1 Esterase Inhibitor
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist

Segment by Application, the Hereditary Angioedema Drug market is segmented into
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies

Regional and Country-level Analysis
The Hereditary Angioedema Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Hereditary Angioedema Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape

and Hereditary Angioedema Drug Market Share Analysis
Hereditary Angioedema Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Hereditary Angioedema Drug business, the date to enter into the Hereditary Angioedema Drug market, Hereditary Angioedema Drug product introduction, recent developments, etc.

The major vendors covered:
Pharming Group NV
Takeda
CSL Limited
IBio Inc.
BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
...